€ million |
|
Note |
|
2024 |
|
2025 |
|||
|---|---|---|---|---|---|---|---|---|---|
Net sales |
|
|
46,606 |
|
45,575 |
||||
Cost of goods sold |
|
|
|
(21,270) |
|
(18,797) |
|||
Gross profit |
|
|
|
25,336 |
|
26,778 |
|||
Selling expenses |
|
|
|
(13,364) |
|
(12,549) |
|||
Research and development expenses |
|
|
|
(6,209) |
|
(5,769) |
|||
General administration expenses |
|
|
|
(2,574) |
|
(2,160) |
|||
Other operating income |
|
|
1,779 |
|
1,802 |
||||
Other operating expenses |
|
|
(5,039) |
|
(9,179) |
||||
EBIT1 |
|
|
|
(71) |
|
(1,077) |
|||
Equity-method income (loss) |
|
|
(132) |
|
(44) |
||||
Financial income |
|
|
|
545 |
|
507 |
|||
Financial expenses |
|
|
|
(2,676) |
|
(2,515) |
|||
Financial result |
|
|
(2,263) |
|
(2,052) |
||||
Income before income taxes |
|
|
|
(2,334) |
|
(3,129) |
|||
Income taxes |
|
|
(212) |
|
(466) |
||||
Income after income taxes |
|
|
|
(2,546) |
|
(3,595) |
|||
of which attributable to noncontrolling interest |
|
|
6 |
|
25 |
||||
of which attributable to Bayer AG stockholders (net income) |
|
|
|
(2,552) |
|
(3,620) |
|||
€ |
|
|
|
|
|
|
|||
Earnings per share |
|
|
|
|
|
||||
Basic |
|
|
|
(2.60) |
|
(3.68) |
|||
Diluted |
|
|
|
(2.60) |
|
(3.68) |
|||
|
|||||||||